By 2026-10-28, Teva will announce the commercial launch of DEGEVMA in the U.S. market.
Posted 2026-09-28 — 30 days before the deadline, stated before the outcome.
The claim
By 2026-10-28, Teva will announce the commercial launch of DEGEVMA in the U.S. market.
Reasoning trace
- FDA approval granted
- Teva prepares supply chain and pricing
- Teva announces launch
Evidence so far
1 confirming · 0 denying signals · 0 verified · 0 broken assumptions. The evidence itself is part of the full dossier.
Probability history
Updated 2 times since mint (last on 2026-09-29) — 70% at mint → 80% today.
What to watch
- leading indicator Teva's investor relations website lists DEGEVMA as 'available' or 'launched' in the United States
- leading indicator DEGEVMA is listed as in-stock or available for order on major U.S. pharmacy benefit manager (PBM) or wholesaler portals
- milestone The FDA publishes a final approval letter for DEGEVMA on its website or in the Federal Register
The full dossier behind this prediction — the evidence trail, the risk analysis, the monetization scenarios — is available on request: [email protected].
Probabilities are calibrated against the system's own resolved history; after the deadline the outcome is resolved and audited — including the calls we get wrong. Nothing on this page is investment advice.